We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals
ZNTL

142 hedge funds and large institutions have $1.34B invested in Zentalis Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 43 increasing their positions, 38 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,075% more call options, than puts

Call options by funds: $1.14M | Put options by funds: $36K

157% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 14

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

18% more funds holding

Funds holding: 120 → 142 (+22)

13% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 38

9% more capital invested

Capital invested by funds: $1.24B → $1.34B (+$107M)

4.78% more ownership

Funds ownership: 115.41% → 120.2% (+4.8%)

Holders
142
Holders Change
+22
Holders Change %
+18.33%
% of All Funds
2.05%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
36
Increased
43
Reduced
38
Closed
14
Calls
$1.14M
Puts
$36K
Net Calls
+$1.11M
Net Calls Change
-$15.4M

Top Buyers

Rank Fund Capital Flow
1
MB
MPM BioImpact
Massachusetts
+$20.9M
2
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$13.4M
3
Verition Fund Management
Verition Fund Management
Connecticut
+$11.1M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$8.06M
5
PBA
Paradigm Biocapital Advisors
New York
+$7.5M

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$13.1M
2
State Street
State Street
Massachusetts
-$8.68M
3
IHAM
Integral Health Asset Management
New York
-$3.79M
4
Bank of America
Bank of America
North Carolina
-$3.34M
5
Ensign Peak Advisors
Ensign Peak Advisors
Utah
-$2.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
26
Boxer Capital
California
$7.09M – – –
Goldman Sachs
27
Goldman Sachs
New York
$5.23M +$538K +39,119 +13%
Rafferty Asset Management
28
Rafferty Asset Management
New York
$4.7M -$854K -62,117 -17%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$4.57M -$3.52K -256 -0.1%
UBS Group
30
UBS Group
Switzerland
$4.22M +$3.68M +267,755 +243,414%
Renaissance Technologies
31
Renaissance Technologies
New York
$4.13M -$651K -47,340 -15%
TD Asset Management
32
TD Asset Management
Ontario, Canada
$4.08M +$944K +68,650 +36%
Citigroup
33
Citigroup
New York
$4.05M +$1.53M +111,169 +76%
Millennium Management
34
Millennium Management
New York
$3.88M +$2.97M +215,627 +702%
Two Sigma Investments
35
Two Sigma Investments
New York
$3.86M +$3.37M +244,995 New
OM
36
Opaleye Management
Massachusetts
$3.15M +$2.75M +200,000 New
MC
37
Mayo Clinic
Minnesota
$2.95M – – –
VOYA Investment Management
38
VOYA Investment Management
Georgia
$2.28M -$58.2K -4,232 -3%
Norges Bank
39
Norges Bank
Norway
$2.25M -$294K -21,386 -13%
Manulife (Manufacturers Life Insurance)
40
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2.08M +$205K +14,921 +13%
PP
41
PDT Partners
New York
$2.07M +$1.81M +131,263 New
N
42
Nuveen
North Carolina
$2.05M – – –
Jane Street
43
Jane Street
New York
$1.96M +$1.08M +78,278 +170%
JF
44
Jump Financial
Illinois
$1.87M +$1.63M +118,648 New
HF
45
HRT Financial
New York
$1.79M +$1.56M +113,750 New
Two Sigma Advisers
46
Two Sigma Advisers
New York
$1.59M +$1.39M +101,000 New
Swiss National Bank
47
Swiss National Bank
Switzerland
$1.54M – – –
Marshall Wace
48
Marshall Wace
United Kingdom
$1.4M – – –
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$1.3M +$27K +1,962 +2%
VFA
50
Values First Advisors
Tennessee
$1.12M +$316K +22,998 +48%
1
2
3 4 5

ZNTL Hedge Fund Activity: Q1 2024 in Review

142 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q1 2024, worth a combined $1.34B — up 8.6% from $1.24B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new ZNTL positions and 14 closed out — a net gain of 22 holders — while 43 added to existing stakes and 38 trimmed.

The largest buyer was MPM BioImpact, opening a new position worth an estimated $20.9M. The largest seller was Vanguard Group, cutting an estimated $13.1M.

  • 142 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q1 2024, up from 120 in Q4 2023.
  • Funds reported $1.34B of Zentalis Pharmaceuticals stock for Q1 2024, up 8.6% quarter-over-quarter.
  • 36 funds opened new Zentalis Pharmaceuticals positions in Q1 2024 and 14 closed out, a net change of +22 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q1 2024 was MPM BioImpact, an estimated $20.9M added.
  • The largest Zentalis Pharmaceuticals seller in Q1 2024 was Vanguard Group, an estimated $13.1M sold.

Based on aggregated 13F filings for Q1 2024.